Provider review
bmiMD tirzepatide review
What bmiMD charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
Read on bmiMD’s own pages on November 21, 2026: limited-time prices of $139 a month month to month, $129 on 3 months, $119 on 6 months and $109 on 12 months ($1,308 for the year), struck through from $349. It scores 80/100 under our written v4.1 scoring guide, #2 of 22 programs scored.
What is distinctive about this programme
State-specific pricing, disclosed
bmiMD is one of only two providers in our dataset that publishes state-specific pricing: California and North Carolina residents pay $379.99 for compounded semaglutide against $289 elsewhere, a 31% difference.
State price variation generally reflects prescriber licensure costs or pharmacy shipping arrangements. Disclosing it is better practice than a single national figure that turns out not to apply at checkout, and it is worth knowing before you compare bmiMD against a national rate.
Pricing sits in the upper band
At $289 semaglutide and $399 tirzepatide, bmiMD is among the more expensive compounded programmes in our dataset. For context, brand Zepbound is $299 direct from LillyDirect and the approved oral orforglipron starts at $149 — both FDA-approved, both below bmiMD's compounded tirzepatide price.
The microdose figure is unusual
bmiMD’s tirzepatide microdose is $349, and its semaglutide microdose is the same $289 as its standard programme (July 2026). Most other microdose programmes in our July records were $147 to $199, and NexLife’s microdose now costs the same as its standard plan ($115 to $129, November 20, 2026). A microdose priced above most competitors’ standard injectable, at a dose below any studied in the trials, is a combination worth asking about directly.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide injectable | $289 | Provider-reported |
| Tirzepatide microdose | $349 | Provider-reported |
| Tirzepatide injectable | $399 | Provider-reported |
Where it holds up
- Publishes state-specific pricing rather than a national figure that changes at checkout
- All-inclusive structure with no separate membership
Where it does not
- Upper-band pricing at $289 semaglutide and $399 tirzepatide
- Compounded tirzepatide costs more than brand Zepbound direct from the manufacturer
- Microdose tirzepatide at $349 is above most competitors' standard injectable pricing
- California and North Carolina residents pay 31% more for semaglutide
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Escalates with dose or not established |
| Lowest captured figure | $289/mo, month-to-month |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
| Category | Points |
|---|---|
| Pricing transparency | 20 |
| Total annual cost | 20 |
| Clinical oversight | 15 |
| Pharmacy transparency | 15 |
| Support | 10 |
| Regulatory disclosure | 10 |
| Accessibility | 10 |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| bmiMD | month_to_month | compounded injectable | not recorded | $399 | not verified | $399 | Recurring | Provider-reported | 2026-07-06 |
| bmiMD | month_to_month | compounded microdose | not recorded | $349 | not verified | $349 | Recurring | Provider-reported | 2026-07-06 |
| bmiMD | month_to_month | compounded injectable | not recorded | $289 | not verified | $289 | Recurring | Provider-reported | 2026-07-06 |
How this sits against the market
The July 2026 all-provider chart that stood here has been retired. Current first-party prices for 28 compounded tirzepatide programs (read October 15, 2026; NexLife November 20, 2026) are on the price index.
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | not verified |
| Shipping | no | not verified |
| Higher-dose surcharge | no | not verified |
| Initial consultation | no | not verified |
| Required laboratory work | no | not verified |
| Cancellation or restocking terms | no | not verified |
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Pharmacy and fulfilment
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where bmiMD sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | not verified | Not answered Verification pending |
| Clinical oversight and care continuity | 20 pts | not verified | Not answered Verification pending |
| State access and operational reliability | 10 pts | not verified | Not answered Verification pending |
| Cancellation, billing and support transparency | 10 pts | not verified | Not answered Verification pending |
Questions readers actually ask
Is bmiMD the cheapest option?
Read on its own page on November 21, 2026: limited-time prices of $139 a month month to month, $129 on 3 months, $119 on 6 months and $109 on 12 months ($1,308 for the year), struck through from $349; ‘Same price at every dose’.
Is compounded tirzepatide the same as Zepbound?
bmiMD scores 80/100 under the written v4.1 scoring guide, #2 of 22 programs scored from pages read November 20–21, 2026. Its weakest category is pharmacy transparency (2 of 15).
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Tirzepatide Provider Comparison ToolTools
- Tirzepatide Price by DosePillar / Money
- Tirzepatide Price Comparison by ProviderPillar / Money
Related coverage
GLP-1 Tirzepatide Review. “bmiMD Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/providers/bmimd/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.